Phaseline

Targets › NKG2D

NKG2D (NKG2-D type II integral membrane protein): drug programs, companies and trials

6 programs from 6 companies in 7 trials: 7 Phase 1; Oncology; next expected readout Dec 2026.

Functions as an activating and costimulatory receptor involved in immunosurveillance upon binding to various cellular stress-inducible ligands displayed at the surface of autologous tumor cells and virus-infected cells. Provides both stimulatory and costimulatory innate immune responses on activated killer (NK) cells, leading to cytotoxic activity. (UniProt, P26718)

Open in Phaseline: the race on NKG2D, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
CytoMed Therapeutics PteAllogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2
NKG2DL-targeting CAR-T cell therapy using allogeneic gamma-delta T cells
NKG2DPhase 1CancerDec 2026
Peking UniversityKD-496
Dual CAR-T cell therapy targeting NKG2D ligands and CLDN18.2
NKG2D, CLDN18Phase 1Gastric CancerJun 2027
Antonio Pérez MartínezNKG2D-CAR memory T cell
chimeric antigen receptor (CAR) T cell targeting NKG2D ligands
NKG2DPhase 1Advanced SarcomaJan 2028
Instituto de Investigación Hospital Universitario La PazAllogeneic CART-NKG2D cells
Anti-NKG2D chimeric antigen receptor Natural-killer group 2, member D T cell therapy
NKG2DPhase 1Precursor Cell Lymphoblastic Leukemia-LymphomaJun 2030
Celyad OncologyCYAD-101
Allogeneic NKG2D-based chimeric antigen receptor T-cell therapy
NKG2DPhase 1Unresectable Metastatic Colorectal CancerFeb 2036
Henan Medical UniversityNKG2D-CAR-NK92 cells
NKG2D-CAR-NK92 cells redirect natural killer cells to recognize NKG2D ligands on tumor cel
NKG2DPhase 1Relapsed/Refractory Solid Tumors–

Conditions

Unresectable Metastatic Colorectal Cancer (2) Gastric Cancer (1) Advanced Sarcoma (1) Relapsed/Refractory Solid Tumors (1) Cancer (1) Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)

Modalities

other (3), protein or peptide (1), small molecule (1)

Companies

Peking University (1) Antonio Pérez Martínez (1) Henan Medical University (1) CytoMed Therapeutics Pte (1) Celyad Oncology (1) Instituto de Investigación Hospital Universitario La Paz (1)

Related targets

CLDN18 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.